Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase EARLY_PHASE1 1Phase 3 1Phase 2 1

Status

Terminated 2Recruiting 2Withdrawn 1Completed 1

Sponsor Class

OTHER 4NIH 1INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 6Breast 1

Conditions

Ovarian Neoplasms 12Fallopian Tube Neoplasms 6Breast Neoplasms 6Endometrial Neoplasms 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Recurrence 1Neoplasm Metastasis 1Mesothelioma 1Fanconi Anemia, Complementation Group D1 1Colorectal Neoplasms 1Advanced Ovarian Cancer 1

Interventions

Carboplatin 159Paclitaxel 153Bevacizumab 85Taxes 48Gemcitabine 48liposomal doxorubicin 47Topotecan 41Cisplatin 35pembrolizumab 33Cyclophosphamide 28olaparib 25Immunoglobulin G 24Disulfides 24Specimen Handling 21Drug Therapy 20Docetaxel 20niraparib 18Magnetic Resonance Spectroscopy 18Doxorubicin 17Biopsy 15mirvetuximab soravtansine 14Hyperthermic Intraperitoneal Chemotherapy 14rucaparib 13Nivolumab 12Cytoreduction Surgical Procedures 11Chemotherapy, Adjuvant 10Albumin-Bound Paclitaxel 10veliparib 9Platinum 9Neoadjuvant Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × talazoparib × Gynecologic × Clear all
NCT03968406 2026-03-11

Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

M.D. Anderson Cancer Center

Phase 1 Recruiting
24 enrolled
Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Endometrial Neoplasms

NCT05071937 2025-06-22

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

University of Pittsburgh

Phase 2 Recruiting
33 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04598321 2023-10-12

BrUOG 390: Neoadjuvant Treatment With Talazoparib

Brown University

Phase 1 Terminated
1 enrolled 10 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03642132 2023-04-06

JAVELIN OVARIAN PARP100

Pfizer

Phase 3 Terminated
79 enrolled 18 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02316834 2022-02-24

POSITION

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Completed
4 enrolled
Gynecologic

Fallopian Tube Neoplasms

NCT02627430 2016-07-26

Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Withdrawn
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡